FundComb
Estimated Control (100%) Announced Transaction verified CPGSupplementsVitaminsVitamins & Supplements

Blackmores acquired by Kirin

Kirin agreed to acquire Blackmores, an Australian vitamins & supplements brand on Apr 26, 2023. The transaction value is shown as USD 1.2bn. The current comp implies EV / revenue of 2.9x. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.

Transaction summary

Target
Blackmores
Acquirer
Kirin
Seller
-
Announced
2023-04-26
Geography
Australia
Tags
CPGSupplementsVitaminsVitamins & Supplements
Type
Acquisition
Deal type
Control
Stake acquired
100%
First added
2026-06-19
Latest update
2026-07-13

Value and multiples

Price / value

USD 1.2B

Enterprise Value | USD

Basis: Public source

EV / revenue

2.9x

Period: varies by source

Basis: FundComb estimate

EV / EBITDA

23.1x

EBITDA basis not stated

Basis: Derived from source data

Basis

  • USD 1.2bn enterprise value is treated as publicly disclosed or derived directly from public source data.
  • EV / revenue is shown as 2.9x based on the available comp inputs.
  • Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
  • EV / EBITDA is recorded as 23.1x. The stored USD 1.2bn value and USD 79.7m EBITDA imply 15.6x; the rounded source inputs are retained with this variance disclosed.

Other reviewed estimates

Transaction comps can involve reported or estimated figures from different sources. FundComb uses the values above as the current canonical comp, while preserving prior reviewed estimates below for context.

Mixed-source metric bundle. Added or updated EBITDA, EV/EBITDA from Thorne HealthTech Schedule 14D-9/A; retained EV/revenue with their original provenance.
EBITDA USD 53.7m | EV / revenue 2.9x | EV / EBITDA 23.1x
Open evidence
EBITDA multiple of 24.3x and EV/sales multiple of 2.9x are from the pasted VMS spreadsheet row, not confirmed in supplied public web evidence.
EV / revenue 2.9x | EV / EBITDA 24.3x

Source summary

Thorne HealthTech Schedule 14D-9/A

Estimated

Precedent transaction row lists implied TEV of $1,241m and TEV/LTM Adjusted EBITDA of 23.1x.

Open source

Blackmores sale to Kirin: Shareholders vote required

Estimated

Shareholder-vote note says the A$95 scheme consideration was fair and reasonable and equated to an acquisition multiple of 23.1x Blackmores EV/EBITDA for the 12 months to Dec. 2022. A separate public article reports the deal implied A$1.88bn equity value and A$1.84bn enterprise value.

Open source